Keybank National Association OH Has $17.27 Million Stock Holdings in Becton Dickinson and Co (NYSE:BDX)

Keybank National Association OH lifted its stake in Becton Dickinson and Co (NYSE:BDX) by 1.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 68,539 shares of the medical instruments supplier’s stock after acquiring an additional 952 shares during the period. Keybank National Association OH’s holdings in Becton Dickinson and were worth $17,273,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Duality Advisers LP grew its stake in shares of Becton Dickinson and by 12.7% in the first quarter. Duality Advisers LP now owns 17,480 shares of the medical instruments supplier’s stock worth $4,365,000 after acquiring an additional 1,970 shares during the last quarter. Meridian Wealth Advisors LLC grew its stake in shares of Becton Dickinson and by 2.7% in the first quarter. Meridian Wealth Advisors LLC now owns 3,787 shares of the medical instruments supplier’s stock worth $946,000 after acquiring an additional 99 shares during the last quarter. Pratt Collard Advisory Partners LLC grew its stake in shares of Becton Dickinson and by 5.1% in the first quarter. Pratt Collard Advisory Partners LLC now owns 2,078 shares of the medical instruments supplier’s stock worth $519,000 after acquiring an additional 100 shares during the last quarter. Investec Asset Management North America Inc. grew its stake in shares of Becton Dickinson and by 5.1% in the first quarter. Investec Asset Management North America Inc. now owns 11,123 shares of the medical instruments supplier’s stock worth $2,778,000 after acquiring an additional 543 shares during the last quarter. Finally, Black Diamond Financial LLC acquired a new stake in shares of Becton Dickinson and in the second quarter worth $562,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Several research analysts recently commented on the company. Piper Jaffray Companies reduced their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. UBS Group reduced their target price on Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, May 10th. KeyCorp reaffirmed an “overweight” rating and issued a $262.00 target price (down from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. Zacks Investment Research raised Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. Finally, BMO Capital Markets reduced their target price on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a research report on Friday, May 10th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $264.27.



In other Becton Dickinson and news, EVP Simon D. Campion sold 2,903 shares of Becton Dickinson and stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $236.94, for a total transaction of $687,836.82. Following the completion of the transaction, the executive vice president now directly owns 9,408 shares of the company’s stock, valued at $2,229,131.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 1,429 shares of Becton Dickinson and stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total value of $347,618.54. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,529 shares of company stock valued at $5,836,116. Company insiders own 0.12% of the company’s stock.

BDX stock traded down $6.32 during midday trading on Wednesday, hitting $247.02. The stock had a trading volume of 26,280 shares, compared to its average volume of 1,214,724. The firm has a market capitalization of $68.66 billion, a price-to-earnings ratio of 22.50, a price-to-earnings-growth ratio of 1.85 and a beta of 1.11. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $265.87. The stock’s 50-day simple moving average is $252.03. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.05 by $0.03. The company had revenue of $4.35 billion during the quarter, compared to analysts’ expectations of $4.37 billion. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The business’s revenue was up 1.7% on a year-over-year basis. During the same period last year, the business earned $2.91 earnings per share. Equities analysts forecast that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.25%. Becton Dickinson and’s payout ratio is presently 27.97%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What is channel trading?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.